At a time when many major AI companies are trying to become AI platform companies, Arterys announced a trio of 3rd party AI alliances that showed how a mature AI platform might work.
Arterys Expands Neuro AI – Arterys launched neuroradiology AI alliances with Combinostics and Cercare Medical, expanding Arterys’ already-comprehensive Neuro AI suite (also includes MRI brain tumor diagnostics, CT stroke & ICH detection, 2D/4D Flow brain MRI). Combinostics’ cNeuro cMRI supports multiple neurological disorder assessments (specifically dementia and multiple sclerosis), while Cercare Perfusion automates brain CT and MRI perfusion map generation and stoke treatment decision making.
Arterys Adds Breast AI – Arterys launched a global distribution agreement with iCAD, making iCAD’s full suite of breast health solutions available in Arterys’ new Breast AI suite. iCAD’s portfolio is certainly broad enough to deserve its own “suite,” ranging from 2D and 3D mammography detection, personalized risk screening and decision support, and density assessments. The Arterys Breast AI suite also makes iCAD available as a cloud-based SaaS solution for the first time (previously only on-premise).
Arterys Platform Impact – Arterys’ integration of multiple complementary AI tools within curated AI Suites is unique and makes a lot of sense. It seems to be far more helpful to provide neurorads with integrated access to a suite of neuro AI tools, than to provide them with one or two tools for every subspecialty.
The Takeaway – Arterys’ new alliances reveal a far more subspecialist-targeted approach than we usually see from AI platforms or marketplaces. It also shows that Arterys is committed to its vendor neutral strategy, effectively doubling its number of active AI partners (previously: Imaging Biometrics & Avicenna.AI in Neuro suite, MILVUE in Chest MSK Suite), while highlighting the value of its cloud-native structure for integrating new partners within the same user interface.
